Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 3/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12896071 | 0.78 | ALDH1A3 (0.35) | ALDH1A3KMT2ASYKPARP10ACACB | |
| SCHEMBL9369865 | 0.76 | TP53 (0.46) | ALDH1A3KMT2ASYKPARP10MAP4K4 | |
| SCHEMBL21097265 | 0.76 | ALDH1A3 (0.34) | ALDH1A3KMT2ATBK1SYKPARP10 | |
| SCHEMBL18484467 | 0.76 | KMT2A (0.38) | ALDH1A3KMT2ASYKPARP10ACACB | |
| SCHEMBL19493806 | 0.76 | ALDH1A3 (0.34) | ALDH1A3KMT2ASYKPARP10ACACB | |
| SCHEMBL355299 | 0.76 | MAP4K4 (0.38) | ALDH1A3KMT2ASYKMAP4K4ALDH1A1 | |
| SCHEMBL708825 | 0.76 | CHRNB2 (0.40) | ALDH1A3KMT2ATBK1SYKPARP10 | |
| SCHEMBL29601182 | 0.76 | CHRNB2 (0.40) | ALDH1A3KMT2ATBK1SYKPARP10 | |
| SCHEMBL12924614 | 0.74 | FTO (0.37) | ALDH1A3KMT2ASYKPARP10ACACB | |
| SCHEMBL12924638 | 0.73 | LMNA (0.36) | ALDH1A3KMT2ASYKPARP10ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145597-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-119923385-A | Inhibitors of RNA helicase DHX9 and uses thereof | 埃克森特治疗公司 | 2025-05-02 | — | — | CN | disclosed |
| US-12233065-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | ACCENT THERAPEUTICS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-4479138-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | Accent Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12162867-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | ACCENT THERAPEUTICS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2024220373-A1 | ASSAYS FOR MONITORING INHIBITION OF RNA HELICASE DHX9 | ACCENT THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240316047-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| US-20240279210-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-4225447-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316047-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX29, DHX9, DDX39B | ALDH1A3 1818/4885KMT2A 2263/4885TBK1 1867/4885 |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | ALDH1A3 4377/4885KMT2A 4667/4885TBK1 240/4885 |
| US-20240279210-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX29, DHX9, DDX39B | ALDH1A3 1401/4885KMT2A 2203/4885TBK1 1972/4885 |
| US-12233065-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | DHX29, DHX9, DDX39B | ALDH1A3 1818/4885KMT2A 2263/4885TBK1 1867/4885 |
| US-12162867-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | DHX29, DHX9, DDX39B | ALDH1A3 1401/4885KMT2A 2203/4885TBK1 1972/4885 |
| US-20250145597-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX9, DHX29, DDX39B | ALDH1A3 1308/4885KMT2A 2280/4885TBK1 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.